Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-29

Clinical Trial Update: Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update on oral ubrogepant for acute treatment of migraine assessing efficacy, safety, and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ubrogepant (ubrogepant)

Snippet

Sponsor: Allergan | Conditions: Migraine, With or Without Aura | Phase 3 | Status: COMPLETED | Results posted: 2019-01-29